China Ulcerative Colitis Market Analysis & Forecast: 2026-2033
The China ulcerative colitis market is estimated to be valued at USD 280.9 Mn in 2026 and expected to reach USD 352.0 Mn by 2033, witnessing a CAGR of 3.3% over the forecast period 2026-2033.
Ulcerative colitis is a category of inflammatory bowel disease that results in inflammation and sores in the digestive tract. Ulcerative colitis affects the inner lining of the large intestine (colon) and rectum. Usually, symptoms can be seen gradually depending upon the severity of inflammation. Mild symptoms can be cured by drug therapy but surgical treatment is needed in case of severity.
Ulcerative colitis may lead to colon cancer if persists for over 8 years or longer. Increasing healthcare preventative measures also progressively becoming more and more sensitive to seek the advantages of the therapy.
The exact cause of ulcerative colitis is not known, but the possible reasons can be genetic factors, environmental changes, or a malfunctioning immune system. The ulcerative colitis can be prevented by simple healthy habits such as eating small meals throughout the day, staying well hydrated throughout the day, avoiding fatty foods, and limiting the intake of high-fiber food.
|
Current Event |
Description and its Impact |
|
Regulatory and Healthcare Policy Developments in China |
|
|
Technological Advances and R&D Innovations |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
|
Category |
Estimated Cost (USD) |
Notes |
|
Direct Medical Cost (per patient/year) |
4,000–6,000 |
Includes hospital visits, diagnostics, 5-ASA, steroids, and supportive care. |
|
Biologics Therapy (per patient/year) |
15,000–20,000 |
Covers infliximab, vedolizumab, ustekinumab, etc.; higher due to infusion and monitoring. |
|
Indirect Costs (per patient/year) |
2,000–3,000 |
Productivity loss, absenteeism, reduced work capacity. |
|
Clinical Trial (Phase I) |
2–5 million |
Small patient cohorts, safety-focused. |
|
Clinical Trial (Phase II) |
10–20 million |
Larger cohorts, efficacy and dose-ranging. |
|
Clinical Trial (Phase III) |
40–100 million |
Multicenter, thousands of patients, regulatory pivotal data. |
|
Drug Development (Preclinical R&D) |
5–10 million |
Lab research, animal studies, formulation. |
|
Regulatory Approval & Filing |
2–5 million |
NMPA submission, documentation, compliance. |
|
Post-Marketing Surveillance (per year) |
1–3 million |
Safety monitoring, real-world evidence collection. |
|
Innovation Investment (Biotech Partnerships) |
20–50 million |
Joint ventures, licensing, technology transfer. |
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
In terms of drug therapy, the 5-aminosalicylates segment is expected to hold 37.8% share of the market in 2026, due to their safety, relatively affordable and work effectively for mild to moderate cases, ensuring wide used. Biologics are becoming more popular, but these drugs still account for the majority of prescriptions, supported by doctors’ familiarity with them and patients prefer oral, long-term maintenance therapy.
In terms of dosage form, the oral segment is expected to lead the market with 62.4% share in 2026, because they are easy to use, adherence, and accessible. Patients prefer tablets and capsules for daily use, especially with drugs like mesalazine. Hospitals and retail pharmacies have a wide stock, which helps them keep their market share. Injectables are becoming more popular with biologics, but most UC patients still prefer oral drugs.
For instance, in February 2026, Everest Medicines stated that the NMPA in China has approved VELSIPITY (etrasimod tablets) for adults with moderately to severely active ulcerative colitis. This oral therapy gives patients who do not respond well to standard or biologic treatments a new option. This is a big step forward in China's UC treatment landscape.
In terms of distribution channel, the hospital pharmacies segment is projected to account for 53.1% share in 2026. Hospital pharmacies are in charge of distribution, especially for biologics and advanced therapies that require special care. Patients with moderate to severe UC often need hospital care, ensuring these outlets capture the largest share. In 2026, hospital pharmacies will still be among the most significant driven by strong rules, physicians prescribing patterns, and easy access to expensive biologics.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 280.9 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 3.3% | 2033 Value Projection: | USD 352.0 Mn |
| Segments covered: |
|
||
| Companies covered: |
AbbVie Inc, Celltrion Healthcare, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche AG, Arena Pharmaceuticals, Takeda Pharmaceuticals Company Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, AstraZeneca, Pfizer Inc., Amgen Inc., BRISTOL-MYERS SQUIBB, ZERIA Pharmaceutical Co., Ltd., InDex Pharmaceuticals Holding AB, Mitsubishi Tanabe Pharma Corporation, Salix Pharmaceuticals, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., EA Pharma Co., Ltd., Theravance Biopharma, and HUTCHMED |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
The fact that ulcerative colitis is gaining traction in China is an important factor for the market growth. A rise in inflammatory bowel disease cases has been caused by rapid urbanization, changes in eating habits, and a lack of physical activity. The need for effective treatments keeps growing as more patients are diagnosed.
This trend is directly driving the China ulcerative colitis market growth, as drug companies and healthcare providers invest into new innovations to help more people with the disease and better manage it over the long term.
Biologics and new small molecules are changing the way ulcerative colitis is treated in China. These new treatments are more effective, have higher remission rates, and improve patients' quality of life compared to traditional treatments.
Doctors are prescribing more biologics because they work better at reducing inflammation by targeting specific areas. This change is greatly increasing the China Ulcerative Colitis Market demand, as patients and healthcare systems prefer advanced treatments that delivery superior outcomes.
China is a great place for drug companies to make more biologics and late-stage pipeline therapies like ozanimod and etrasimod available. Doctors are increasingly choosing targeted treatments over regular drugs because they have higher remission rates and fewer side effects.
This trend makes it easier for strategic partnerships, licensing agreements, and local production to speed up adoption. As these treatments become more popular, the China Ulcerative Colitis Market forecast shows strong growth due to new ideas and better patient outcomes.
For instance, in Janury 2026, Caldera Biotech and Qyuns Therapeutics are collaborating on a new drug that targets the TL1A and IL-23 pathways for inflammatory bowel diseases like ulcerative colitis. The partnership is based in China and its main goal is to expand pipeline therapies to meet unmet needs. It also focuses on new advanced biologics for patients with chronic gastrointestinal disorders.
Share
Share
About Author
Ghanshyam Shrivastava - With over 20 years of experience in the management consulting and research, Ghanshyam Shrivastava serves as a Principal Consultant, bringing extensive expertise in biologics and biosimilars. His primary expertise lies in areas such as market entry and expansion strategy, competitive intelligence, and strategic transformation across diversified portfolio of various drugs used for different therapeutic category and APIs. He excels at identifying key challenges faced by clients and providing robust solutions to enhance their strategic decision-making capabilities. His comprehensive understanding of the market ensures valuable contributions to research reports and business decisions.
Ghanshyam is a sought-after speaker at industry conferences and contributes to various publications on pharma industry.
Missing comfort of reading report in your local language? Find your preferred language :
Transform your Strategy with Exclusive Trending Reports :
Frequently Asked Questions
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
